• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bayer wins second approval in China for Eylea eye drug

May 17, 2018 By Sarah Faulkner

BayerBayer (ETR:BAYN) said today that its eye drug, Eyelea, was approved by the Chinese authorities to treat patients with wet age-related macular degeneration.

The pharmaceutical giant’s aflibercept injection is already cleared in China to treat visual impairment due to diabetic macular edema.

Age-related macular degeneration accounts for 8.7% of all blindness, according to Bayer – that’s three million people worldwide. Out of all AMD patients, wet-AMD accounts for more than 80% of legal blindness, the company said.

“Neovascular age-related macular degeneration is a rapidly progressive eye disease which can lead to permanent vision loss in just a few months if left untreated,” Joerg Moeller, head of R&D at Bayer, said in prepared remarks. “We are delighted that with this approval, patients in China with this devastating disease will soon have access to a therapy that has been demonstrated in clinical trials and real world clinical settings to improve vision and long-term outcomes.”

In a trial conducted in China, wet-AMD patients treated with Eylea experienced statistically significant vision improvement compared to patients treated with photodynamic therapy.

Eylea, which is sold by Regeneron Pharmaceuticals (NSDQ:REGN) in the U.S., is a blockbuster drug approved to treat patients with conditions like macular edema following retinal vein occlusion and diabetic macular edema. Approximately 20 million vials of Eylea have been sold since the product launched, according to Bayer.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Bayer AG, Regeneron

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS